I understand.
Let's go back to the economic aspect.
As I said, Ottawa has capped the health transfer escalator at 3%, even though costs are doubling annually. From a purely economic point of view, if the money coming in is less than the costs in question, what can be done to tackle the problem of antimicrobial resistance, for example?